Agenus Announces Nature Medicine Publication of Phase 2 UNICORN Trial
Agenus announced publication of its multicenter Phase 2 UNICORN trial in Nature Medicine. The headline says the trial demonstrated deep responses with neoadjuvant BOT+BAL in resectable colon cancer.
Story updates
11:43:04 AM UTC
SquawkNews
In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major path
11:43:30 AM UTC
SquawkNews
Agenus meldet 29 Prozent komplette pathologische Remissionen mit BOT+BAL bei MSS-Darmkrebs in Phase